Big pharma companies open to deals with small biotechs, conference hears FEBRUARY 28, 2011 http://www.vancouversun.com/business/pharma+companies+open+deals+with+small+biotechs+conference+hears/4362074/story.html
good reading. i like this bit...
"It's extremely important to Merck that we have a lot of partnerships to supplement our internal research. In terms of revenue, around 63 per cent of Merck's current revenue is derived from products for which we need a license from another company to sell that product - whether it be a vaccine where we have a lot of technologies or a compound that we licensed in from a partner.
"This shows you that the future of Merck is very dependent on the kinds of partnerships we have done and we are hoping to do more of as we meet with you at this conference."--Barbara Yanni, Merck VP
ADO Price at posting:
7.8¢ Sentiment: Hold Disclosure: Held
